Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Zymeworks Inc (ZYME)

Zymeworks Inc (ZYME)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,977,930
  • Shares Outstanding, K 45,627
  • Annual Sales, $ 29,540 K
  • Annual Income, $ -145,440 K
  • 60-Month Beta 0.99
  • Price/Sales 64.09
  • Price/Cash Flow N/A
  • Price/Book 3.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.91
  • Number of Estimates 5
  • High Estimate -0.62
  • Low Estimate -1.06
  • Prior Year -0.70
  • Growth Rate Est. (year over year) -30.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.28 +54.85%
on 09/04/20
45.59 -0.55%
on 09/14/20
+15.58 (+52.35%)
since 08/18/20
3-Month
28.71 +57.92%
on 08/17/20
45.59 -0.55%
on 09/14/20
+8.41 (+22.77%)
since 06/18/20
52-Week
20.33 +123.02%
on 03/18/20
52.75 -14.05%
on 01/22/20
+19.50 (+75.46%)
since 09/18/19

Most Recent Stories

More News
Zymeworks to Present at Upcoming Investor Conferences

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in three upcoming virtual investor conferences....

WFC : 25.13 (+0.08%)
ZYME : 45.34 (+4.59%)
Is a Surprise Coming for Zymeworks (ZYME) This Earnings Season?

Zymeworks (ZYME) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ZYME : 45.34 (+4.59%)
Zymeworks Inc. (ZYME) Reports Q2 Loss, Tops Revenue Estimates

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 26.74% and 44.72%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

ZYME : 45.34 (+4.59%)
Zymeworks Reports 2020 Second Quarter Financial Results

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the quarter ended June 30, 2020.

ZYME : 45.34 (+4.59%)
Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ZYME : 45.34 (+4.59%)
Zymeworks (ZYME) Catches Eye: Stock Jumps 7.7%

Zymeworks (ZYME) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

ZYME : 45.34 (+4.59%)
AKCA : 18.15 (+0.06%)
Moving Average Crossover Alert: Zymeworks

Zymeworks Inc. (ZYME) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

ZYME : 45.34 (+4.59%)
Zymeworks to Present at the Jefferies 2020 Virtual Healthcare Conference

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that the Company will present at the upcoming Jefferies 2020 Virtual Healthcare...

ZYME : 45.34 (+4.59%)
Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered...

ZYME : 45.34 (+4.59%)
Zymeworks Inc (ZYME) Reports Q1 Loss, Tops Revenue Estimates

Zymeworks Inc (ZYME) delivered earnings and revenue surprises of 28.89% and 6.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

ZYME : 45.34 (+4.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade ZYME with:

Business Summary

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered...

See More

Key Turning Points

2nd Resistance Point 46.66
1st Resistance Point 46.00
Last Price 45.34
1st Support Level 44.07
2nd Support Level 42.80

See More

52-Week High 52.75
Last Price 45.34
Fibonacci 61.8% 40.37
Fibonacci 50% 36.54
Fibonacci 38.2% 32.71
52-Week Low 20.33

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar